Published in Infect Immun on February 01, 1998
Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev (2001) 3.58
The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro. J Bacteriol (2000) 2.10
A hag mutant of Moraxella catarrhalis strain O35E is deficient in hemagglutination, autoagglutination, and immunoglobulin D-binding activities. Infect Immun (2002) 1.35
The Moraxella catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells. Infect Immun (2004) 1.30
Contribution of Moraxella catarrhalis type IV pili to nasopharyngeal colonization and biofilm formation. Infect Immun (2007) 1.21
Metabolic analysis of Moraxella catarrhalis and the effect of selected in vitro growth conditions on global gene expression. Infect Immun (2007) 1.17
The UspA2 protein of Moraxella catarrhalis is directly involved in the expression of serum resistance. Infect Immun (2005) 1.16
Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect Immun (2006) 1.10
Inactivation of the Moraxella catarrhalis 7169 ferric uptake regulator increases susceptibility to the bactericidal activity of normal human sera. Infect Immun (2003) 1.05
Quantitative detection of Moraxella catarrhalis in nasopharyngeal secretions by real-time PCR. J Clin Microbiol (2003) 1.04
Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis. Infect Immun (1999) 0.99
Analysis of the immunological responses to transferrin and lactoferrin receptor proteins from Moraxella catarrhalis. Infect Immun (1999) 0.94
Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis. Infect Immun (2005) 0.89
Modular arrangement of allelic variants explains the divergence in Moraxella catarrhalis UspA protein function. Infect Immun (2008) 0.86
A conserved tetranucleotide repeat is necessary for wild-type expression of the Moraxella catarrhalis UspA2 protein. J Bacteriol (2006) 0.85
Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model. PLoS One (2013) 0.83
Intranasal immunization of the combined lipooligosaccharide conjugates protects mice from the challenges with three serotypes of Moraxella catarrhalis. PLoS One (2011) 0.76
Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis. Vaccine (2011) 0.76
A simple method for displaying the hydropathic character of a protein. J Mol Biol (1982) 150.65
Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol (1978) 29.77
Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry (1978) 22.56
Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease. Infect Immun (1982) 3.18
Molecular analysis of bacterial pathogens in otitis media with effusion. JAMA (1995) 2.94
Branhamella catarrhalis respiratory infections. Rev Infect Dis (1988) 2.51
A set of two monoclonal antibodies specific for the cell surface-exposed 39K major outer membrane protein of Haemophilus influenzae type b defines all strains of this pathogen. Infect Immun (1983) 1.95
Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease. Arch Intern Med (1986) 1.92
A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect Immun (1993) 1.84
Bacteriology of acute otitis media: a new perspective. J Pediatr (1992) 1.80
Surface-exposed and antigenically conserved determinants of outer membrane proteins of Branhamella catarrhalis. Infect Immun (1989) 1.73
Development of bactericidal antibody during Branhamella catarrhalis infection. J Infect Dis (1985) 1.71
Isolation of the outer membrane of Branhamella catarrhalis. Microb Pathog (1989) 1.70
A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival in vivo. J Infect Dis (1993) 1.63
A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies. J Infect Dis (1994) 1.62
Comparison of the outer membrane proteins of 50 strains of Branhamella catarrhalis. J Infect Dis (1988) 1.61
Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. J Pediatr (1994) 1.57
Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect Immun (1990) 1.52
Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum. J Clin Microbiol (1990) 1.50
Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood. J Infect Dis (1990) 1.49
Increase in bronchopulmonary infection due to branhamella catarrhalis. Br Med J (Clin Res Ed) (1986) 1.45
Branhamella (Neisseria) catarrhalis systemic disease in humans. Case reports and review of the literature. Arch Intern Med (1981) 1.39
Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect Immun (1996) 1.39
Growth of Moraxella catarrhalis with human transferrin and lactoferrin: expression of iron-repressible proteins without siderophore production. Infect Immun (1994) 1.35
The major heat-modifiable outer membrane protein CD is highly conserved among strains of Branhamella catarrhalis. Mol Microbiol (1993) 1.33
Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin. Infect Immun (1996) 1.32
Molecular characterization of FrpB, the 70-kilodalton iron-regulated outer membrane protein of Neisseria meningitidis. Infect Immun (1995) 1.32
Antigenic drift of non-encapsulated Haemophilus influenzae major outer membrane protein P2 in patients with chronic bronchitis is caused by point mutations. Mol Microbiol (1994) 1.31
Immune response to outer membrane antigens of Moraxella catarrhalis in children with otitis media. Infect Immun (1992) 1.28
Outer membrane protein CD of Branhamella catarrhalis: sequence conservation in strains recovered from the human respiratory tract. Microb Pathog (1995) 1.19
Mapping of bactericidal epitopes on the P2 porin protein of nontypeable Haemophilus influenzae. Infect Immun (1994) 1.16
The epidemiology of respiratory tract pathogens in southern Netherlands. Eur Respir J (1988) 1.15
Heterogeneity and structure of antibody-combining sites. Ann N Y Acad Sci (1970) 1.11
The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol Med Microbiol (1997) 1.11
Serum antibodies to outer membrane proteins (OMPs) of Moraxella (Branhamella) catarrhalis in patients with bronchiectasis: identification of OMP B1 as an important antigen. Infect Immun (1995) 1.11
Branhamella catarrhalis as a cause of bacteremic pneumonia. Scand J Infect Dis (1983) 1.01
Fine mapping of outer membrane protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae. Infect Immun (1996) 0.93
Human immune response against outer membrane proteins of Moraxella (Branhamella) catarrhalis determined by immunoblotting and enzyme immunoassay. Clin Diagn Lab Immunol (1995) 0.92
Mapping of a strain-specific bactericidal epitope to the surface-exposed loop 5 on the P2 porin protein of non-typeable Haemophilus influenzae. Microb Pathog (1994) 0.90
Effect of immunization of pulmonary clearance of Moraxella catarrhalis in an animal model. J Infect Dis (1993) 0.90
Immune response to Moraxella catarrhalis in children with otitis media: opsonophagocytosis with antigen-coated latex beads. Ann Otol Rhinol Laryngol (1994) 0.90
An enzyme-linked immunosorbent assay for the determination of human IgG subclass antibodies directed against Branhamella catarrhalis. J Immunol Methods (1990) 0.87
Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media. Antimicrob Agents Chemother (1991) 0.86
Antibody response to P-protein in patients with Branhamella catarrhalis infections. Am J Med (1990) 0.82
Mapping of the combining sites of antibodies specific to polyalanine chains. Ann N Y Acad Sci (1971) 0.80
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med (1994) 6.92
Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature (1992) 6.37
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Synaptic vesicle fusion complex contains unc-18 homologue bound to syntaxin. Nature (1993) 4.93
Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med (1988) 4.17
The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med (1991) 3.94
Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med (1993) 3.67
Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J (1993) 3.38
Identification of immunogenic outer membrane proteins of Haemophilus influenzae type b in the infant rat model system. Infect Immun (1981) 3.37
Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis. J Infect Dis (1981) 3.28
Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease. Infect Immun (1982) 3.18
A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group. J Pediatr (1976) 3.13
Group B streptococci: the new challenge in neonatal infections. J Pediatr (1973) 2.90
A diffusible cytotoxin of Haemophilus ducreyi. Proc Natl Acad Sci U S A (1997) 2.89
Antigenic and phenotypic variations of Haemophilus influenzae type b lipopolysaccharide and their relationship to virulence. Infect Immun (1986) 2.84
A minor high-molecular-weight outer membrane protein of Haemophilus influenzae type b is a protective antigen. Infect Immun (1985) 2.81
The spectrum of group B streptococcal infections in infancy. Am J Dis Child (1974) 2.72
The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem (1999) 2.72
Screening for cephalosporin-resistant Streptococcus pneumoniae with the Kirby-Bauer disk susceptibility test. J Clin Microbiol (1993) 2.69
Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet (1974) 2.67
Report of the Task Force on Diagnosis and Management of Meningitis. Pediatrics (1986) 2.62
Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (1993) 2.61
Cytoplasmic 3-hydroxy-3-methylglutaryl coenzyme A synthase from the hamster. I. Isolation and sequencing of a full-length cDNA. J Biol Chem (1986) 2.60
Immunoprotection of rats against Haemophilus influenzae type B disease mediated by monoclonal antibody against a haemophilus outer-membrane protein. Lancet (1982) 2.53
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1995) 2.50
Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J Biol Chem (1992) 2.48
Detection of antibody-accessible proteins on the cell surface of Haemophilus influenzae type b. Infect Immun (1981) 2.41
Two-dimensional gel electrophoretic comparison of proteins from virulent and avirulent strains of Mycoplasma pneumoniae. Infect Immun (1979) 2.34
Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. J Exp Med (1990) 2.33
Multiple genes encode nuclear factor 1-like proteins that bind to the promoter for 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Proc Natl Acad Sci U S A (1988) 2.31
Sepsis neonatorum. N Engl J Med (1981) 2.27
Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis. Antimicrob Agents Chemother (1980) 2.27
Cerebrospinal fluid evaluation in neonates: comparison of high-risk infants with and without meningitis. J Pediatr (1976) 2.26
Monoclonal antibodies directed against a cell surface-exposed outer membrane protein of Haemophilus influenzae type b. Infect Immun (1982) 2.23
Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics (1989) 2.23
In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins. Antimicrob Agents Chemother (1980) 2.21
Use of polymerase chain reaction and rabbit infectivity testing to detect Treponema pallidum in amniotic fluid, fetal and neonatal sera, and cerebrospinal fluid. J Clin Microbiol (1991) 2.20
Comparative efficacy of ceftriaxone and cefuroxime for treatment of bacterial meningitis. J Pediatr (1989) 2.17
Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr (1993) 2.16
Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20 S proteasome. J Biol Chem (1994) 2.15
Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet (1980) 2.15
The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis. Am J Dis Child (1972) 2.13
The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro. J Bacteriol (2000) 2.10
A gene cluster involved in the utilization of both free heme and heme:hemopexin by Haemophilus influenzae type b. J Bacteriol (1995) 2.08
Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis. Antimicrob Agents Chemother (1982) 2.08
Conservation of epitopes in the oligosaccharide portion of the lipooligosaccharide of Haemophilus influenzae type b. Infect Immun (1987) 2.06
Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr (1993) 2.05
An unusual human IgM antibody with a protruding HCDR3 and high avidity for its peptide ligands. Mol Immunol (2000) 2.04
Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis 035E. Infect Immun (1998) 2.03
Isolation of mutants of Mycoplasma pneumoniae defective in hemadsorption. Infect Immun (1979) 2.02
Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications. J Pediatr (1990) 2.01
Characterization of hemadsorption-negative mutants of Mycoplasma pneumoniae. Infect Immun (1981) 2.00
PA700, an ATP-dependent activator of the 20 S proteasome, is an ATPase containing multiple members of a nucleotide-binding protein family. J Biol Chem (1994) 2.00
Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants. J Pediatr (1981) 2.00
Relatively penicillin-resistant pneumococcal infections in pediatric patients. Pediatr Infect Dis (1984) 1.98
Identification of a cytolethal distending toxin gene locus and features of a virulence-associated region in Actinobacillus actinomycetemcomitans. Infect Immun (1999) 1.97
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli. Pediatr Res (1976) 1.96
Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (1994) 1.96
A set of two monoclonal antibodies specific for the cell surface-exposed 39K major outer membrane protein of Haemophilus influenzae type b defines all strains of this pathogen. Infect Immun (1983) 1.95
Regional blood flow and oxygen transport in septic shock. Crit Care Med (1993) 1.95
In organello formaldehyde crosslinking of proteins to mtDNA: identification of bifunctional proteins. Proc Natl Acad Sci U S A (2000) 1.94
A protective epitope of Moraxella catarrhalis is encoded by two different genes. Infect Immun (1997) 1.89
Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides. J Immunol (1994) 1.85
Purification of component A of Rab geranylgeranyl transferase: possible identity with the choroideremia gene product. Cell (1992) 1.85
A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect Immun (1993) 1.84
Coprecipitation of lipopolysaccharide and the 39,000-molecular-weight major outer membrane protein of Haemophilus influenzae type b by lipopolysaccharide-directed monoclonal antibody. Infect Immun (1985) 1.84
Characterization of the Moraxella catarrhalis uspA1 and uspA2 genes and their encoded products. J Bacteriol (1999) 1.82
A functional tonB gene is required for both utilization of heme and virulence expression by Haemophilus influenzae type b. Infect Immun (1994) 1.81
Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J (1999) 1.81
Identification of a genetic locus of Haemophilus influenzae type b necessary for the binding and utilization of heme bound to human hemopexin. Proc Natl Acad Sci U S A (1992) 1.80
Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. J Biol Chem (1990) 1.79
Molecular cloning and expression of palmitoyl-protein thioesterase. J Biol Chem (1994) 1.79
Adverse fetal outcome following maternal rubella after the first trimester of pregnancy. JAMA (1969) 1.78
Single-dose penicillin prophylaxis against neonatal group B streptococcal infections. A controlled trial in 18,738 newborn infants. N Engl J Med (1980) 1.78
A temperature-dependent rabbit model for production of dermal lesions by Haemophilus ducreyi. J Infect Dis (1991) 1.77
Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children. Lancet (1983) 1.77
Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr (1980) 1.71